Roberto Pili

  • 11420 Citations
  • 53 h-Index
1987 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Publications

Psychological status and immunological parameters of institutionalized aged.

Bartoloni, C., Guidi, L., Antico, L., Pariante, C. M., Di Giovanni, A., Pili, R., Cursi, F., Tricerri, A., Tempesta, E. & Frasca, D., Jan 1 1991, In : Panminerva medica. 33, 3, p. 164-169 6 p.

Research output: Contribution to journalArticle

4 Scopus citations

Psychological status, life and social conditions: A study in a population of institutionalized elderly people

Bartoloni, C., Guidi, L., di Giovanni, A. L., Antico, L., Cursi, F., Pili, R., Tricerri, A., Janiri, L., Mannelli, P., Pariante, C., Menini, E., Carbonin, P. & Gambassi, G., May 1993, In : International Journal of Geriatric Psychiatry. 8, 5, p. 419-426 8 p.

Research output: Contribution to journalArticle

1 Scopus citations

Provenge: Combating prostate cancer with a vengeance?

Schwaab, T. & Pili, R., Aug 1 2011, In : Expert Review of Vaccines. 10, 8, p. 1113-1114 2 p.

Research output: Contribution to journalEditorial

2 Scopus citations

Protein arginine methyltransferase 5 functions as an epigenetic activator of the androgen receptor to promote prostate cancer cell growth

Deng, X., Shao, G., Zhang, H. T., Li, C., Zhang, D., Cheng, L., Elzey, B. D., Pili, R., Ratliff, T. L., Huang, J. & Hu, C. D., Mar 2 2017, In : Oncogene. 36, 9, p. 1223-1231 9 p.

Research output: Contribution to journalArticle

36 Scopus citations

Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition

Chintala, S., Najrana, T., Toth, K., Cao, S., Durrani, F. A., Pili, R. & Rustum, Y. M., Jul 17 2012, In : BMC Cancer. 12, 293.

Research output: Contribution to journalArticle

38 Scopus citations

Pretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with ketoconazole: Association with outcome and predictive nomogram

Keizman, D., Gottfried, M., Ish-Shalom, M., Maimon, N., Peer, A., Neumann, A., Rosenbaum, E., Kovel, S., Pili, R., Sinibaldi, V., Carducci, M. A., Hammers, H., Eisenberger, M. A. & Sella, A., Dec 31 2012, In : Oncologist. 17, 12, p. 1508-1514 7 p.

Research output: Contribution to journalArticle

64 Scopus citations
3 Scopus citations

Predictors of Complete Pathologic Response (pT0) to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma

Pokuri, V. K., Syed, J. R., Yang, Z., Field, E. P., Cyriac, S., Pili, R., Levine, E. G., Azabdaftari, G., Trump, D. L., Guru, K. & George, S., Feb 1 2016, In : Clinical Genitourinary Cancer. 14, 1, p. e59-e65

Research output: Contribution to journalArticle

31 Scopus citations

Pre-clinical models of renal carcinoma and their utility in drug development

Salumbides, B. C., Lehet, K. M., Ndikuyeze, G. & Pili, R., Dec 1 2009, In : Current Protocols in Pharmacology. SUPPL.47, p. 14.13.1-14.13.19

Research output: Contribution to journalReview article

3 Scopus citations

Preclinical and clinical studies with the multi-kinase inhibitor CEP-701 as treatment for prostate cancer demonstrate the inadequacy of PSA response as a primary endpoint

Collins, C., Carducci, M. A., Eisenberger, M. A., Isaacs, J. T., Partin, A. W., Pili, R., Sinibaldi, V. J., Walczak, J. S. & Denmeade, S. R., Sep 2007, In : Cancer Biology and Therapy. 6, 9, p. 1356-1363 8 p.

Research output: Contribution to journalArticle

Open Access
15 Scopus citations

Posttranscription regulation of prostate cancer growth

Shen, L. & Pili, R., Jan 1 2008, In : Cancer Journal. 14, 1, p. 46-53 8 p.

Research output: Contribution to journalReview article

11 Scopus citations

Population pharmacokinetic-pharmacodynamic model of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acidin cancer patients

Li, J., Jameson, M. B., Baguley, B. C., Pili, R. & Baker, S. D., Apr 1 2008, In : Clinical Cancer Research. 14, 7, p. 2102-2110 9 p.

Research output: Contribution to journalArticle

22 Scopus citations

Platelets take up the monoclonal antibody bevacizumab

Verheul, H. M. W., Lolkema, M. P. J., Qian, D. Z., Hilkes, Y. H. A., Liapi, E., Akkerman, J. W. N., Pili, R. & Voest, E. E., Sep 15 2007, In : Clinical Cancer Research. 13, 18, p. 5341-5347 7 p.

Research output: Contribution to journalArticle

83 Scopus citations

Phase I trials of anti-ENPP3 antibody–drug conjugates in advanced refractory renal cell carcinomas

Thompson, J. A., Motzer, R. J., Molina, A. M., Choueiri, T. K., Heath, E. I., Redman, B. G., Sangha, R. S., Ernst, D. S., Pili, R., Kim, S. K., Reyno, L., Wiseman, A., Trave, F., Anand, B., Morrison, K., Doñate, F. & Kollmannsberger, C. K., Sep 15 2018, In : Clinical Cancer Research. 24, 18, p. 4399-4406 8 p.

Research output: Contribution to journalArticle

9 Scopus citations

Phase I study of the mTOR inhibitor everolimus in combination with the histone deacetylase inhibitor panobinostat in patients with advanced clear cell renal cell carcinoma

Wood, A., George, S., Adra, N., Chintala, S., Damayanti, N. & Pili, R., Aug 1 2020, In : Investigational New Drugs. 38, 4, p. 1108-1116 9 p.

Research output: Contribution to journalArticle

1 Scopus citations

Phase i study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours

Pili, R., Salumbides, B., Zhao, M., Altiok, S., Qian, D., Zwiebel, J., Carducci, M. A. & Rudek, M. A., Jan 3 2012, In : British Journal of Cancer. 106, 1, p. 77-84 8 p.

Research output: Contribution to journalArticle

103 Scopus citations

Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors

Siu, L. L., Pili, R., Duran, I., Messersmith, W. A., Chen, E. X., Sullivan, R., MacLean, M., King, S., Brown, S., Reid, G. K., Li, Z., Kalita, A. M., Laille, E. J., Besterman, J. M., Martell, R. E. & Carducci, M. A., Sep 15 2008, In : Journal of Clinical Oncology. 26, 12, p. 1940-1947 8 p.

Research output: Contribution to journalArticle

108 Scopus citations

Phase I Study of Dalteparin in Combination With Sunitinib in Patients With Metastatic Clear Cell Renal Carcinoma

Wentink, M. Q., Verheul, H. M. W., Pal, S. K., George, S., Voortman, J., Danchaivijitr, P., Adelaiye, R., Poslinski, D., Groman, A., Hutson, A. & Pili, R., Feb 2018, In : Clinical Genitourinary Cancer. 16, 1, p. e1-e9

Research output: Contribution to journalArticle

3 Scopus citations

Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer

Rathkopf, D., Carducci, M. A., Morris, M. J., Slovin, S. F., Eisenberger, M. A., Pili, R., Denmeade, S. R., Kelsen, M., Curley, T., Halter, M., Collins, C., Fleisher, M., Heller, G., Baker, S. D. & Scher, H. I., 2008, In : Journal of Clinical Oncology. 26, 18, p. 2959-2965 7 p.

Research output: Contribution to journalArticle

21 Scopus citations

Phase II study on the addition of ASA404 (vadimezan; 5,6- dimethylxanthenone-4-acetic acid) to docetaxel in CRMPC

Pili, R., Rosenthal, M. A., Mainwaring, P. N., Van Hazel, G., Srinivas, S., Dreicer, R., Goel, S., Leach, J., Wong, S. & Clingan, P., May 15 2010, In : Clinical Cancer Research. 16, 10, p. 2906-2914 9 p.

Research output: Contribution to journalArticle

47 Scopus citations

Phase II Study of Imatinib Mesylate in Patients with Prostate Cancer with Evidence of Biochemical Relapse After Definitive Radical Retropubic Prostatectomy or Radiotherapy

Bajaj, G. K., Zhang, Z., Garrett-Mayer, E., Drew, R., Sinibaldi, V., Pili, R., Denmeade, S. R., Carducci, M. A., Eisenberger, M. A. & DeWeese, T. L., Mar 1 2007, In : Urology. 69, 3, p. 526-531 6 p.

Research output: Contribution to journalArticle

34 Scopus citations

Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC)

Monk, P., Liu, G., Stadler, W. M., Geyer, S., Huang, Y., Wright, J., Villalona-Calero, M., Wade, J., Szmulewitz, R., Gupta, S., Mortazavi, A., Dreicer, R., Pili, R., Dawson, N., George, S. & Garcia, J. A., Oct 1 2018, In : Investigational New Drugs. 36, 5, p. 919-926 8 p.

Research output: Contribution to journalArticle

4 Scopus citations

Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer

Pili, R., Hag̈gman, M., Stadler, W. M., Gingrich, J. R., Assikis, V. J., Bjor̈k, A., Nordle, O., Forsberg, G., Carducci, M. A. & Armstrong, A. J., Oct 20 2011, In : Journal of Clinical Oncology. 29, 30, p. 4022-4028 7 p.

Research output: Contribution to journalArticle

155 Scopus citations

Phase II evaluation of docetaxel plus exisulind in patients with androgen independent prostate carcinoma

Sinibaldi, V. J., Elza-Brown, K., Schmidt, J., Eisenberger, M. A., Rosenbaum, E., Denmeade, S. R., Pili, R., Walczak, J., Baker, S. D., Zahurak, M. & Carducci, M. A., Aug 1 2006, In : American Journal of Clinical Oncology: Cancer Clinical Trials. 29, 4, p. 395-398 4 p.

Research output: Contribution to journalArticle

14 Scopus citations

Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer

Carducci, M. A., Musib, L., Kies, M. S., Pili, R., Truong, M., Brahmer, J. R., Cole, P., Sullivan, R., Riddle, J., Schmidt, J., Enas, N., Sinha, V., Thornton, D. E. & Herbst, R. S., Sep 1 2006, In : Journal of Clinical Oncology. 24, 25, p. 4092-4099 8 p.

Research output: Contribution to journalArticle

165 Scopus citations

Phase 3 assessment of the automated bone scan index as a prognostic imaging biomarker of overall survival in men with metastatic castration-resistant prostate cancer a secondary analysis of a randomized clinical trial

Armstrong, A. J., Anand, A., Edenbrandt, L., Bondesson, E., Bjartell, A., Widmark, A., Sternberg, C. N., Pili, R., Tuvesson, H., Nordle, Ö., Carducci, M. A. & Morris, M. J., Jul 2018, In : JAMA Oncology. 4, 7, p. 944-951 8 p.

Research output: Contribution to journalArticle

19 Scopus citations

Pharmacological polyamine catabolism upregulation with methionine salvage pathway inhibition as an effective prostate cancer therapy

Affronti, H. C., Rowsam, A. M., Pellerite, A. J., Rosario, S. R., Long, M. D., Jacobi, J. J., Bianchi-Smiraglia, A., Boerlin, C. S., Gillard, B. M., Karasik, E., Foster, B. A., Moser, M., Wilton, J. H., Attwood, K., Nikiforov, M. A., Azabdaftari, G., Pili, R., Phillips, J. G., Casero, R. A. & Smiraglia, D. J., Dec 1 2020, In : Nature communications. 11, 1, 52.

Research output: Contribution to journalArticle

Open Access

Pentastatin-1, a collagen IV derived 20-mer peptide, suppresses tumor growth in a small cell lung cancer xenograft model

Koskimaki, J. E., Karagiannis, E. D., Tang, B. C., Hammers, H., Watkins, D. N., Pili, R. & Popel, A. S., Feb 1 2010, In : BMC Cancer. 10, 29.

Research output: Contribution to journalArticle

33 Scopus citations

Patient-derived organoids as a potential model to predict response to PD-1/PD-L1 checkpoint inhibitors

Scognamiglio, G., De Chiara, A., Parafioriti, A., Armiraglio, E., Fazioli, F., Gallo, M., Aversa, L., Camerlingo, R., Cacciatore, F., Colella, G., Pili, R. & de Nigris, F., Nov 26 2019, In : British Journal of Cancer. 121, 11, p. 979-982 4 p.

Research output: Contribution to journalArticle

Open Access
1 Scopus citations

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Oudard, S., Negrier, S., Szczylik, C., Pili, R., Bjarnason, G. A., Garcia-del-Muro, X., Sosman, J. A., Solska, E., Wilding, G., Thompson, J. A., Kim, S. T., Chen, I., Huang, X. & Figlin, R. A., Aug 1 2009, In : Journal of Clinical Oncology. 27, 22, p. 3584-3590 7 p.

Research output: Contribution to journalArticle

1708 Scopus citations

Nuclear factor erythroid 2-related factor-2 activity controls 4-hydroxynonenal metabolism and activity in prostate cancer cells

Pettazzoni, P., Ciamporcero, E., Medana, C., Pizzimenti, S., Dal Bello, F., Minero, V. G., Toaldo, C., Minelli, R., Uchida, K., Dianzani, M. U., Pili, R. & Barrera, G., Oct 15 2011, In : Free Radical Biology and Medicine. 51, 8, p. 1610-1618 9 p.

Research output: Contribution to journalArticle

24 Scopus citations

Needs assessments can identify scores on HRQOL questionnaires that represent problems for patients: An illustration with the Supportive Care Needs Survey and the QLQ-C30

Snyder, C. F., Blackford, A. L., Brahmer, J. R., Carducci, M. A., Pili, R., Stearns, V., Wolff, A. C., Dy, S. M. & Wu, A. W., Aug 1 2010, In : Quality of Life Research. 19, 6, p. 837-845 9 p.

Research output: Contribution to journalArticle

33 Scopus citations

NCCN task force report: Optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy

Hudes, G. R., Carducci, M. A., Choueiri, T. K., Esper, P., Jonasch, E., Kumar, R., Margolin, K. A., Michaelson, M. D., Motzer, R. J., Pili, R., Roethke, S. & Srinivas, S., Mar 24 2011, In : JNCCN Journal of the National Comprehensive Cancer Network. 9, SUPPL. 1, p. S1-S29

Research output: Contribution to journalArticle

43 Scopus citations

Nanosponge-encapsulated camptothecin exerts anti-tumor activity in human prostate cancer cells

Minelli, R., Cavalli, R., Ellis, L., Pettazzoni, P., Trotta, F., Ciamporcero, E., Barrera, G., Fantozzi, R., Dianzani, C. & Pili, R., Nov 20 2012, In : European Journal of Pharmaceutical Sciences. 47, 4, p. 686-694 9 p.

Research output: Contribution to journalArticle

43 Scopus citations

Muscadine grape skin extract (MPX) in men with biochemically recurrent prostate cancer: A randomized, multicenter, placebo-controlled clinical trial

Paller, C. J., Zhou, X. C., Heath, E. I., Taplin, M. E., Mayer, T., Stein, M. N., Bubley, G. J., Pili, R., Hudson, T., Kakarla, R., Abbas, M. M., Anders, N. M., Dowling, D., King, S., Bruns, A. B., Wagner, W. D., Drake, C. G., Antonarakis, E. S., Eisenberger, M. A., Denmeade, S. R. & 3 others, Rudek, M. A., Rosner, G. L. & Carducci, M. A., Jan 15 2018, In : Clinical Cancer Research. 24, 2, p. 306-315 10 p.

Research output: Contribution to journalArticle

10 Scopus citations

Multimodal imaging guided preclinical trials of vascular targeting in prostate cancer

Kalmuk, J., Folaron, M., Buchinger, J., Pili, R. & Seshadri, M., 2015, In : Oncotarget. 6, 27, p. 24376-24392 17 p.

Research output: Contribution to journalArticle

6 Scopus citations

Modulation of chemotherapeutic efficacy by vascular disrupting agents: Optimizing the sequence and schedule

Wang, E. S., Pili, R. & Seshadri, M., Mar 1 2012, In : Journal of Clinical Oncology. 30, 7, p. 760-761 2 p.

Research output: Contribution to journalLetter

15 Scopus citations

Modified synthesis and antiangiogenic activity of Linomide

Khan, S. R., Mhaka, A., Pili, R. & Isaacs, J. T., Feb 26 2001, In : Bioorganic and Medicinal Chemistry Letters. 11, 4, p. 451-452 2 p.

Research output: Contribution to journalArticle

16 Scopus citations

Modeling the cost of management options for stage I nonseminomatous germ cell tumors: A decision tree analysis

Link, R. E., Allaf, M. E., Pili, R. & Kavoussi, L. R., Dec 1 2005, In : Journal of Clinical Oncology. 23, 24, p. 5762-5773 12 p.

Research output: Contribution to journalArticle

16 Scopus citations

Modeling spontaneous metastatic renal cell carcinoma (mRCC) in mice following nephrectomy

Tracz, A., Mastri, M., Lee, C. R., Pili, R. & Ebos, J. M. L., Apr 29 2014, In : Journal of Visualized Experiments. 86, e51485.

Research output: Contribution to journalArticle

9 Scopus citations

Mind the gap: Potential for rebounds during antiangiogenic treatment breaks

Ebos, J. M. L. & Pili, R., Jul 15 2012, In : Clinical Cancer Research. 18, 14, p. 3719-3721 3 p.

Research output: Contribution to journalArticle

12 Scopus citations

Methods in laboratory investigation: A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor

Passaniti, A., Taylor, R. M., Pili, R., Guo, Y., Long, P. V., Haney, J. A., Pauly, R. R., Grant, D. S. & Martin, G. R., Jan 1 1992, In : Laboratory Investigation. 67, 4, p. 519-528 10 p.

Research output: Contribution to journalArticle

738 Scopus citations

Mental disorders in obese patients with and without metabolic syndrome

Carpiniello, B., Pinna, F., Pili, R., Velluzzi, F. & Loviselli, A., Jan 1 2011, In : International Journal of Psychiatry in Medicine. 42, 4, p. 369-375 7 p.

Research output: Contribution to journalArticle

4 Scopus citations

Mechanisms of action of tasquinimod on the tumour microenvironment

Raymond, E., Dalgleish, A., Damber, J. E., Smith, M. & Pili, R., Jan 2014, In : Cancer Chemotherapy and Pharmacology. 73, 1, p. 1-8 8 p.

Research output: Contribution to journalReview article

34 Scopus citations

Mechanism of action and clinical activity of tasquinimod in castrate-resistant prostate cancer

Gupta, N., Ustwani, O. A., Shen, L. & Pili, R., Feb 12 2014, In : OncoTargets and Therapy. 7, p. 223-234 12 p.

Research output: Contribution to journalArticle

16 Scopus citations

Marimastat in the treatment of patients with biochemically relapsed prostate cancer: A prospective randomized, double-blind, phase I/II trial

Rosenbaum, E., Zahurak, M., Sinibaldi, V., Carducci, M. A., Pili, R., Laufer, M., DeWeese, T. L. & Eisenberger, M. A., Jun 15 2005, In : Clinical Cancer Research. 11, 12, p. 4437-4443 7 p.

Research output: Contribution to journalArticle

43 Scopus citations

Major response to cyclophosphamide and prednisone in recurrent castration-resistant prostate cancer

Batty, N., Yarlagadda, N. & Pili, R., Aug 1 2013, In : JNCCN Journal of the National Comprehensive Cancer Network. 11, 8, p. 911-915 5 p.

Research output: Contribution to journalArticle

Open Access
1 Scopus citations

Lysosomal sequestration of sunitinib: A novel mechanism of drug resistance

Gotink, K. J., Broxterman, H. J., Labots, M., De Haas, R. R., Dekker, H., Honeywell, R. J., Rudek, M. A., Beerepoot, L. V., Musters, R. J., Jansen, G., Griffioen, A. W., Assaraf, Y. G., Pili, R., Peters, G. J. & Verheul, H. M. W., Dec 1 2011, In : Clinical Cancer Research. 17, 23, p. 7337-7346 10 p.

Research output: Contribution to journalArticle

175 Scopus citations

Low-protein diet in cancer: Ready for prime time?

Pili, R. & Fontana, L., Jul 1 2018, In : Nature Reviews Endocrinology. 14, 7, p. 384-386 3 p.

Research output: Contribution to journalArticle

1 Scopus citations

Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancer

Armstrong, A. J., Häggman, M., Stadler, W. M., Gingrich, J. R., Assikis, V., Polikoff, J., Damber, J. E., Belkoff, L., Nordle, Ö., Forsberg, G., Carducci, M. A. & Pili, R., Dec 15 2013, In : Clinical Cancer Research. 19, 24, p. 6891-6901 11 p.

Research output: Contribution to journalArticle

37 Scopus citations